The UK and US have reached a important trade agreement that will maintain no levies on UK drug shipments entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to boost spending on medicines through the NHS. This move guarantees that duties on these crucial exports will be held at nothing for a period of 36 months.
This deal follows earlier warnings to significantly raise duties on patented drug imports, with increases discussed up to one hundred percent.
"This deal between the Britain strengthens the worldwide climate for cutting-edge drugs and brings long-overdue equity to American-British medicine commerce," a statement noted.
Trade Importance
Drugs represent one of the UK's most significant export categories to the US, which is by far the biggest buyer for leading British pharmaceutical firms.
Export figures reveal that in the year to the end of September, the UK exported drugs worth £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards employment, stimulates funding and sets the stage for the UK to become a international leader for biotech and pharma," a minister remarked.
Key UK Commitments
The agreement entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments exceeded twenty percent.
Recent Tensions
The deal comes amid a ongoing tension between the sector and the ministers over spending levels and approval rates.
These tensions were intensified by claims that American patients were paying several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or cancelled, while substantial investments have been pledged toward projects in the United States.
One official acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
